BMA annual meeting: Pregabalin must be made a controlled drug, BMA says

Pregabalin should be reclassified as a controlled drug to tackle widespread problems of misuse and addiction, the BMA has said.

Delegates at the BMA’s annual representative meeting in Bournemouth on 28 June voted in favour of a motion saying that the BMA should “lobby the appropriate authorities to make pregabalin a controlled drug.”

Pregabalin is currently a prescription only drug and is licensed for the treatment of neuropathic pain and …